News
Read about our latest product developments and partnerships, industry advances and events.
Our Pipeline
Eblasakimab
Eblasakimab is a novel, fully human, monoclonal IgG4 antibody that binds specifically to the Interleukin (IL)-13 receptor, preventing signaling of IL-4 and IL-13 through the Type 2 receptor. Eblasakimab is currently being developed as a treatment for moderate-to-severe atopic dermatitis (AD).
Farudodstat
Farudodstat is an orally active, potent inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH), that suppresses T cell proliferation and secretion of Interferon Gamma (IFNγ) by blocking de novo production of pyrimidines required for DNA replication.
About Us
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients.